• Careers
  • Contact Us
  • Home
  • About Us
    • Our Aim & Values
    • Company Focus
    • Corporate Responsibility
  • Products
  • Business Development
    • Licensing
    • Partnership Advisory Committee
  • News



Xediton Pharmaceuticals Inc. announces a share purchase agreement with Valeo Pharma

by xediton | Feb 7, 2025 | Uncategorized

OAKVILLE, ONTARIO, February 5, 2025,—   Xediton Pharmaceuticals Inc., (“Xediton” or the “Purchaser”)  a Canadian Specialty Pharmaceutical company, announced today that it has closed a share purchase agreement with Valeo Pharma Inc. (“Valeo” or the “Company”),  in its...

Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada

by xediton | May 15, 2023 | Uncategorized

Parsippany, New Jersey and Ontario, Canada, May 15, 2023 – Melinta Therapeutics, LLC (Melinta) and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA® (delafloxacin), KIMYRSA®...

Quick Links

  • Home
  • About Us
  • Products
  • Business Development
  • News & Press Releases
  • Careers
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Trade Policy

Contact Us

2020 Winston Park Drive, Suite 402
Oakville, Ontario, L6H 6X7, Canada

Toll Free: 1-855-646-3225
Toll Free: 1-888-933-4866
Phone: 905-286-9111
Fax: 905-286-9101
Email: info@xediton.com

Copyright 2025 © Xediton Pharmaceuticals Inc.

Designed by Web Sharx